Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
PathAI makes AI-powered pathology software and provides lab services that help biopharma companies, researchers, and pathology labs analyze tissue images and diagnose disease.
When you get a biopsy, a doctor slices a bit of tissue onto a glass slide, stains it pink and purple, and peers through a microscope to figure out what's wrong. PathAI is a company that teaches computers to help with that job. Its software analyzes images of tissue and flags things a human eye might miss, and it also runs its own lab services for the drug companies and research teams that need this kind of analysis done at scale.
The business has two main arms. One sells software to pathology labs and hospitals β tools that help pathologists read slides faster and more consistently. The other serves biopharma companies, which use PathAI's technology during drug trials to measure whether a treatment is actually changing the tissue in the way it's supposed to. That second arm matters a lot: a drugmaker running a cancer trial needs precise, reproducible readings of thousands of tissue samples, and an AI that reads them the same way every time is genuinely valuable. PathAI also offers lab services directly, so customers can hand over the samples and get the analysis back rather than buying software and doing it themselves. The pitch to customers is partly about speed and partly about consistency. Human pathologists are highly trained but they can disagree with each other, and their readings can vary. A well-trained algorithm gives the same answer on the same image every time. That is why regulators and drug developers have taken an interest β the FDA has been working on a path for approving these tools, and getting a diagnostic cleared for clinical use is a big deal for any company in this space.
PathAI was founded in Boston in 2016 by Andy Beck, a pathologist, and it grew with backing from venture investors. It competes with other digital pathology players, including Roche-owned efforts and a cluster of startups, and the field got more crowded when Danaher's Leica Biosystems and others pushed into digital slides. The hard part of this business is not writing clever code β it's earning trust. Hospitals move slowly, regulators demand evidence, and drug companies need proof the numbers hold up. PathAI's bet is that years of validation work and partnerships with major pharma firms will make it the default choice rather than a science project.
Saved answer Β· last researched 16 Nov 2026